ASCO 2024 | COMBI-AD: long-term follow-up of dabrafenib and trametinib in BRAF-mutated melanoma

Georgina Long, PhD, MBBS, FRACP, FAHMS, University of Sydney, North Sydney, Australia, discusses the final results from the Phase III COMBI-AD trial (NCT01682083) of adjuvant dabrafenib with trametinib in patients with BRAF-mutated stage III melanoma. With a median follow-up of 100 months, the study shows that the combination treatment significantly improved relapse-free survival (RFS) and distant-metastasis-free survival (DMFS) compared to placebo. The safety profile remained consistent with previous reports, affirming the long-term efficacy of dabrafenib plus trametinib in reducing relapse and metastasis in high-risk melanoma. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.